Advanced search
1 file | 10.68 MB Add to list

Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism

(2022) GUT. 71(1). p.129-147
Author
Organization
Abstract
Objective:Pancreatic ductal adenocarcinoma (PDAC) is the most lethal malignancy and lacks effective treatment. We aimed to understand molecular mechanisms of the intertwined interactions between tumour stromal components in metastasis and to provide a new paradigm for PDAC therapy. Design: Two unselected cohorts of 154 and 20 patients with PDAC were subjected to correlation between interleukin (IL)-33 and CXCL3 levels and survivals. Unbiased expression profiling, and genetic and pharmacological gain-of-function and loss-of-function approaches were employed to identify molecular signalling in tumour-associated macrophages (TAMs) and myofibroblastic cancer-associated fibroblasts (myoCAFs). The role of the IL-33–ST2–CXCL3–CXCR2 axis in PDAC metastasis was evaluated in three clinically relevant mouse PDAC models. Results: IL-33 was specifically elevated in human PDACs and positively correlated with tumour inflammation in human patients with PDAC. CXCL3 was highly upregulated in IL-33-stimulated macrophages that were the primary source of CXCL3. CXCL3 was correlated with poor survival in human patients with PDAC. Mechanistically, activation of the IL-33–ST2–MYC pathway attributed to high CXCL3 production. The highest level of CXCL3 was found in PDAC relative to other cancer types and its receptor CXCR2 was almost exclusively expressed in CAFs. Activation of CXCR2 by CXCL3 induced a CAF-to-myoCAF transition and α-smooth muscle actin (α-SMA) was uniquely upregulated by the CXCL3–CXCR2 signalling. Type III collagen was identified as the CXCL3–CXCR2-targeted adhesive molecule responsible for myoCAF-driven PDAC metastasis. Conclusions: Our work provides novel mechanistic insights into understanding PDAC metastasis by the TAM-CAF interaction and targeting each of these signalling components would provide an attractive and new paradigm for treating pancreatic cancer.
Keywords
Gastroenterology, pancreatic cancer, myofibroblasts, macrophages, interleukins, chemokines, GROWTH, IMMUNOTHERAPY, FIBROBLASTS, INHIBITION, SURVIVAL, TARGETS, BIOLOGY

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 10.68 MB

Citation

Please use this url to cite or link to this publication:

MLA
Sun, Xiaoting, et al. “Inflammatory Cell-Derived CXCL3 Promotes Pancreatic Cancer Metastasis through a Novel Myofibroblast-Hijacked Cancer Escape Mechanism.” GUT, vol. 71, no. 1, 2022, pp. 129–47, doi:10.1136/gutjnl-2020-322744.
APA
Sun, X., He, X., Zhang, Y., Hosaka, K., Andersson, P., Wu, J., … Cao, Y. (2022). Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. GUT, 71(1), 129–147. https://doi.org/10.1136/gutjnl-2020-322744
Chicago author-date
Sun, Xiaoting, Xingkang He, Yin Zhang, Kayoko Hosaka, Patrik Andersson, Jing Wu, Jieyu Wu, et al. 2022. “Inflammatory Cell-Derived CXCL3 Promotes Pancreatic Cancer Metastasis through a Novel Myofibroblast-Hijacked Cancer Escape Mechanism.” GUT 71 (1): 129–47. https://doi.org/10.1136/gutjnl-2020-322744.
Chicago author-date (all authors)
Sun, Xiaoting, Xingkang He, Yin Zhang, Kayoko Hosaka, Patrik Andersson, Jing Wu, Jieyu Wu, Xu Jing, Qiqiao Du, Xiaoli Hui, Bo Ding, Ziheng Guo, An Hong, Xuan Liu, Yan Wang, Qing Ji, Rudi Beyaert, Yunlong Yang, Qi Li, and Yihai Cao. 2022. “Inflammatory Cell-Derived CXCL3 Promotes Pancreatic Cancer Metastasis through a Novel Myofibroblast-Hijacked Cancer Escape Mechanism.” GUT 71 (1): 129–147. doi:10.1136/gutjnl-2020-322744.
Vancouver
1.
Sun X, He X, Zhang Y, Hosaka K, Andersson P, Wu J, et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. GUT. 2022;71(1):129–47.
IEEE
[1]
X. Sun et al., “Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism,” GUT, vol. 71, no. 1, pp. 129–147, 2022.
@article{8711940,
  abstract     = {{Objective:Pancreatic ductal adenocarcinoma (PDAC) is the most lethal malignancy and lacks effective treatment. We aimed to understand molecular mechanisms of the intertwined interactions between tumour stromal components in metastasis and to provide a new paradigm for PDAC therapy.

Design: Two unselected cohorts of 154 and 20 patients with PDAC were subjected to correlation between interleukin (IL)-33 and CXCL3 levels and survivals. Unbiased expression profiling, and genetic and pharmacological gain-of-function and loss-of-function approaches were employed to identify molecular signalling in tumour-associated macrophages (TAMs) and myofibroblastic cancer-associated fibroblasts (myoCAFs). The role of the IL-33–ST2–CXCL3–CXCR2 axis in PDAC metastasis was evaluated in three clinically relevant mouse PDAC models.

Results: IL-33 was specifically elevated in human PDACs and positively correlated with tumour inflammation in human patients with PDAC. CXCL3 was highly upregulated in IL-33-stimulated macrophages that were the primary source of CXCL3. CXCL3 was correlated with poor survival in human patients with PDAC. Mechanistically, activation of the IL-33–ST2–MYC pathway attributed to high CXCL3 production. The highest level of CXCL3 was found in PDAC relative to other cancer types and its receptor CXCR2 was almost exclusively expressed in CAFs. Activation of CXCR2 by CXCL3 induced a CAF-to-myoCAF transition and α-smooth muscle actin (α-SMA) was uniquely upregulated by the CXCL3–CXCR2 signalling. Type III collagen was identified as the CXCL3–CXCR2-targeted adhesive molecule responsible for myoCAF-driven PDAC metastasis.

Conclusions: Our work provides novel mechanistic insights into understanding PDAC metastasis by the TAM-CAF interaction and targeting each of these signalling components would provide an attractive and new paradigm for treating pancreatic cancer.}},
  author       = {{Sun, Xiaoting and He, Xingkang and Zhang, Yin and Hosaka, Kayoko and Andersson, Patrik and Wu, Jing and Wu, Jieyu and Jing, Xu and Du, Qiqiao and Hui, Xiaoli and Ding, Bo and Guo, Ziheng and Hong, An and Liu, Xuan and Wang, Yan and Ji, Qing and Beyaert, Rudi and Yang, Yunlong and Li, Qi and Cao, Yihai}},
  issn         = {{0017-5749}},
  journal      = {{GUT}},
  keywords     = {{Gastroenterology,pancreatic cancer,myofibroblasts,macrophages,interleukins,chemokines,GROWTH,IMMUNOTHERAPY,FIBROBLASTS,INHIBITION,SURVIVAL,TARGETS,BIOLOGY}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{129--147}},
  title        = {{Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism}},
  url          = {{http://doi.org/10.1136/gutjnl-2020-322744}},
  volume       = {{71}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: